Individualized Medication Guidance for Prostate Cancer CapitalBio

Features of Individualized Medication Guidance for Prostate Cancer

• Targeted therapy-Including SNV, InDel, CNV and gene rearrangement, comprehensively guide targeted drug use.

• Immunotherapy-Detect TMB and MSI indicators, as well as positive and negative immune-related genes, provide information to guide immunosuppressive therapy.

• Chemotherapy- Detect chemotherapeutic drug loci associated with prostate cancer, suggesting sensitivity and toxic side effects of chemotherapeutic drugs.

• Hereditary risk assessment- Covering HRR pathway genes, suggesting pathogenic and suspected pathogenic variants, guiding PARP inhibitor therapy, and suggesting genetic risk based on family tumor history and other information.

• Prostate cancer patients who have relapsed, drug-resistant problem.

• Prostate cancer patients who have been diagnosed with prostate cancer, and need liquid biopsy for targeted therapy and immunotherapy.

• Late-stage newly diagnosed prostate cancer patients who need targeted therapy and immunotherapy.